Neogen (NEOG) Free Cash Flow Growth (1y) (2011 - 2026)
Neogen (NEOG) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 28.87% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 14.12% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 0.77% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 13.29% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 142.84% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -11.68% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 750.00% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 0.40% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -14.34% |
| 10 | Neogen | 2.61 Bn | 2.42 Bn | 107.80 Mn | 8,633.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 8,633.33% |
| Feb 28, 2026 | 182.34% |
| Nov 30, 2025 | -66.34% |
| Aug 31, 2025 | 76.66% |
| May 31, 2025 | -86.00% |
| Feb 28, 2025 | 78.42% |
| Nov 30, 2024 | 365.41% |
| Aug 31, 2024 | -639.36% |
| May 31, 2024 | -96.19% |
| Feb 29, 2024 | -93.44% |
| Nov 30, 2023 | 71.78% |
| Aug 31, 2023 | 71.92% |
| May 31, 2023 | 733.70% |
| Feb 28, 2023 | -49,469.23% |
| Nov 30, 2022 | -321.70% |
| Aug 31, 2022 | -223.84% |
| May 31, 2022 | -46.40% |
| Feb 28, 2022 | -101.97% |
| Nov 30, 2021 | -10.54% |
| Aug 31, 2021 | 4.93% |